Using model-system genetics for drug-based target discovery.
- Authors
- Matthews, D J.; Kopczynski, J
- Year
- 2001
- Journal
- Drug discovery today
- PMID
- 11165187
- DOI
- 10.1016/s1359-6446(00)01612-3
The combination of medicinal chemistry and model-organism genetics is emerging as a powerful tool for the discovery and validation of drug targets. Model systems can be used to identify the cognate target for compounds that demonstrate in vivo efficacy but have unknown mechanisms of action. Alternatively, drugs with known cognate targets can be used to probe biochemical pathways in model organisms, revealing new targets and mechanisms within these pathways. In both cases, the availability of human genomic sequence data is opening up new opportunities for accelerating target discovery.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genomewide Association Study of Alcohol Dependence Identifies Risk Loci Altering Ethanol-Response Behaviors in Model Organisms. | 2017 | 28226201 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Potentials and Pitfalls of Cross-Translational Models of Cognitive Impairment. | Al Dahhan NZ et al. | — | 2019 | → |
| Cross-species molecular dissection across alcohol behavioral domains. | Farris SP et al. | — | 2018 | → |
| Genomewide Association Study of Alcohol Dependence Identifies Risk Loci Altering Ethanol-Response Behaviors in Model Organisms. | Adkins AE et al. | — | 2017 | → |
| Caenorhabditis elegans-based in vivo screening of bioactives from marine sponge-associated bacteria against Vibrio alginolyticus. | Durai S et al. | — | 2013 | → |
| Protein analysis based on molecular beacon probes and biofunctionalized nanoparticles. | Shi H et al. | — | 2010 | → |
| Evaluation of animal models of neurobehavioral disorders. | van der Staay FJ et al. | — | 2009 | → |
| From genes to drugs: target validation in Caenorhabditis elegans. | Sluder AE et al. | — | 2004 | → |
| Genomics and proteomics tools for compound mode-of-action studies in drug discovery. | Kley N et al. | — | 2004 | → |
| Using C. elegans to screen for targets of ethanol and behavior-altering drugs. | Davies AG et al. | — | 2004 | → |
| Model systems in drug discovery: chemical genetics meets genomics. | Carroll PM et al. | — | 2003 | → |
| Target discovery. | Lindsay MA | — | 2003 | → |
| Targeting the CREB pathway for memory enhancers. | Tully T et al. | — | 2003 | → |
| The immunosuppressant FK506 uncovers a positive regulatory cross-talk between the Hog1p and Gcn2p pathways. | Rodriguez-Hernandez CJ et al. | — | 2003 | → |
| High-throughput gene mapping in Caenorhabditis elegans. | Swan KA et al. | — | 2002 | → |
| Combinatorial libraries and biological discovery. | Gray NS | — | 2001 | → |